Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 2 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready
Fusion Pharmaceuticals Inc. currently has 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are handled by 5 distinct examiners, showing a high ratio of examiners to total pending actions. Despite the number of examiners involved, the prosecution is concentrated within only 2 distinct art units, which implies a focused technical scope for the pending applications.
MOSHER, ERIC PARKER is the busiest examiner for the company, with 2 pending office actions under their review. This leaves the remaining pending actions to be distributed among the other distinct examiners. The concentration in the distinct art units suggests that while the examiners vary, the procedural environment remains consistent across the portfolio.
With 6 pending office actions and 5 distinct examiners, the company faces a set of individual perspectives within a narrow organizational framework. This structure allows for specialized technical arguments that are relevant across the entire portfolio while requiring tailored communication strategies for each of the 5 examiners involved in the process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 2 (33%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSHER, ERIC PARKER | 2 | 100.0% | +0.0% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
| BAEK, JONGHWAN NMN | 1 | 60.0% | +0.0% |
| DICKINSON, PAUL W | 1 | 63.1% | +9.5% |
| CRAIGO, BAHAR ALAWI | 1 | 47.1% | +27.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833849 | NTSR1-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY | MOSHER, ERIC PARKER | — |
| 18703995 | METHODS OF TREATING CANCER | MOSHER, ERIC PARKER | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18541618 | COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOX | DICKINSON, PAUL W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16619433 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | CRAIGO, BAHAR ALAWI | 5d |
| 18833850 | PSMA-TARGETED RADIOPHARMACEUTICALS AND CHECKPOINT INHIBITOR COMBINATION THERAPY | CRAIG, KAILA ANGELIQUE | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833849 | NTSR1-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY | MOSHER, ERIC PARKER | — | §103§112DP | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18833850 | PSMA-TARGETED RADIOPHARMACEUTICALS AND CHECKPOINT INHIBITOR COMBINATION THERAPY | CRAIG, KAILA ANGELIQUE | — | §103Other | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18703995 | METHODS OF TREATING CANCER | MOSHER, ERIC PARKER | — | §103§112DP | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18541584 | COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND AND FOLFIRINOX | BAEK, JONGHWAN NMN | 1618 | §103Other | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18541618 | COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOX | DICKINSON, PAUL W | — | §101§103DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 16619433 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | CRAIGO, BAHAR ALAWI | 1699 | §112Other | Non-Final OA | 5d | Pending | Dec 04, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial